Production of Minor Ginsenoside CK from Major Ginsenosides by Biotransformation and Its Advances in Targeted Delivery to Tumor Tissues Using Nanoformulations

• Published in: Nanomaterials (Basel, Switzerland) Vol. 12; no. 19; p. 3427
• Main Authors: Murugesan, Mohanapriya, Mathiyalagan, Ramya, Boopathi, Vinothini, Kong, Byoung Man, Choi, Sung-Keun, Lee, Chang-Soon, Yang, Deok Chun, Kang, Se Chan, Thambi, Thavasyappan
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 30.09.2022; MDPI
• Subjects: Acids; Bioactive compounds; Bioavailability; Biological activity; Biotransformation; Blood circulation; Cancer; Cardiovascular diseases; Cell membranes; Diabetes mellitus; Diseases; Drying agents; Genetic transformation; Ginseng; ginsenoside; Ginsenosides; Herbal medicine; Hydrophobicity; Mass production; Membrane permeability; Molecular weight; nanoformulation; Panax ginseng; Permeability; pharmacological activity; Plant extracts; Review; South Korea; Sulfur; transformation; Transformations; Tumors; South Korea
• ISSN: 2079-4991; 2079-4991
• DOI: 10.3390/nano12193427

For over 2000 years, ginseng (roots of Panax ginseng C.A. Meyer) has been used as a traditional herbal medicine. Ginsenosides are bioactive compounds present in ginseng responsible for the pharmacological effects and curing various acute diseases as well as chronic diseases including cardiovascular disease, cancer and diabetes. Structurally, ginsenosides consist of a hydrophobic aglycone moiety fused with one to four hydrophilic glycoside moieties. Based on the position of sugar units and their abundance, ginsenosides are classified into major and minor ginsenosides. Despite the great potential of ginsenosides, major ginsenosides are poorly absorbed in the blood circulation, resulting in poor bioavailability. Interestingly, owing to their small molecular weight, minor ginsenosides exhibit good permeability across cell membranes and bioavailability. However, extremely small quantities of minor ginsenosides extracted from ginseng plants cannot fulfill the requirement of scientific and clinical studies. Therefore, the production of minor ginsenosides in mass production is a topic of interest. In addition, their poor solubility and lack of targetability to tumor tissues limits their application in cancer therapy. In this review, various methods used for the transformation of major ginsenosides to minor ginsenoside compound K (CK) are summarized. For the production of CK, various transformation methods apply to major ginsenosides. The challenges present in these transformations and future research directions for producing bulk quantities of minor ginsenosides are discussed. Furthermore, attention is also paid to the utilization of nanoformulation technology to improve the bioavailability of minor ginsenoside CK.